Related Experiment Video
Updated: May 5, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
Hannah E Goyne1, Martin J Cannon
1Department of Pathology, University of Arkansas for Medical Sciences , Little Rock, AR , USA.
Abstract:
Clinical optimism for dendritic cell vaccination against ovarian cancer has been tempered by the knowledge that tumors avail themselves of multiple mechanisms of immune evasion, thus blunting the efficacy of therapeutic vaccination. Mechanisms of immune suppression include infiltration by regulatory T cells (Treg) and myeloid suppressor cell populations, expression of co-inhibitory receptors, and expression of indoleamine 2,3-dioxygenase (IDO). Expression of both B7-H1 and IDO are associated with differentiation and recruitment of Treg, and clinical studies have shown that each of these mechanisms correlates independently with increased morbidity and mortality in ovarian cancer patients. In sharp contrast, recent studies have indicated that Th17 cell infiltration in ovarian cancer correlates with improved patient outcomes and prolonged overall survival. Given that IDO plays a pivotal role in the balance between Treg and Th17 immunity, elucidation of the mechanisms that regulate IDO activity and immune suppression may lead to novel adjuvants to boost the clinical efficacy of dendritic cell vaccination against ovarian cancer and other malignancies.
Insights
Dendritic cell vaccines for ovarian cancer face challenges from tumor immune evasion, including regulatory T cells (Treg) and indoleamine 2,3-dioxygenase (IDO). Understanding IDO’s role in immune suppression could improve cancer vaccine efficacy.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Ovarian cancer treatments, including dendritic cell vaccination, are hindered by tumor immune evasion mechanisms.
- Immune suppression involves regulatory T cells (Treg), myeloid suppressor cells, co-inhibitory receptors, and indoleamine 2,3-dioxygenase (IDO).
- IDO and B7-H1 expression correlate with Treg recruitment and poorer patient outcomes in ovarian cancer.
Purpose of the Study:
- To investigate the role of indoleamine 2,3-dioxygenase (IDO) in regulating the balance between immune-suppressive Treg and immune-stimulatory Th17 cells in ovarian cancer.
- To identify potential targets for novel adjuvants to enhance dendritic cell vaccination efficacy.
Main Methods:
- Analysis of immune cell infiltration (Treg, Th17) in ovarian tumors.
- Assessment of IDO and B7-H1 expression in relation to immune cell populations and patient survival.
- Review of existing clinical data on immune evasion mechanisms and therapeutic vaccination.
Main Results:
- Tumor-infiltrating regulatory T cells (Treg) and indoleamine 2,3-dioxygenase (IDO) are associated with immune suppression and negative patient outcomes in ovarian cancer.
- In contrast, Th17 cell infiltration correlates with improved survival.
- IDO plays a critical role in modulating the Treg/Th17 balance.
Conclusions:
- Targeting IDO activity may overcome immune suppression in ovarian cancer.
- Elucidating IDO regulatory mechanisms could lead to improved dendritic cell vaccine adjuvants.
- Novel strategies are needed to enhance dendritic cell vaccination efficacy against ovarian cancer and other malignancies.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...